Poor Result Reporting Rate in Cell Therapy Trials Registered at ClinicalTrials.gov

Takaharu Negoro1,2, Hanayuki Okura1,2, Shigekazu Hayashi1

  • 1Center for Reverse Translational Research, Osaka Habikino Medical Center, Osaka Prefectural Hospital Organization, Habikino City, Japan.

Insights

Clinical trial result reporting is inadequate, especially for cell and gene therapy (CTGT) trials. Cell and gene therapy trials show lower reporting rates, while ex vivo gene therapy trials demonstrate higher rates. Solutions are needed to improve transparency.

Area of Science:

  • Clinical research transparency
  • Biomedical data reporting
  • Health outcomes research

Background:

  • Ethical obligations require full disclosure of clinical trial methodologies and findings.
  • Previous studies indicated inadequate reporting of clinical trial results on ClinicalTrials.gov, with about half of trials not reported appropriately.
  • A prior study highlighted insufficient result reporting for gene and cell therapy (CT) trials in regenerative medicine.

Purpose of the Study:

  • To assess the reporting rates of clinical trial results across all disease areas, distinguishing between gene therapy (GT) and cell therapy (CT).
  • To analyze the impact of different therapeutic modalities (biologics, CT, ex vivo GT, in vivo GT) on result reporting.
  • To identify factors influencing the reporting of clinical trial outcomes on ClinicalTrials.gov and in publications.

Main Methods:

  • Analysis of 5539 interventional clinical trials registered on ClinicalTrials.gov (2010-2019) classified by AdisInsight database as biologics (BLG), CT, ex vivo GT, and in vivo GT.
  • Assessment of result reporting status through ClinicalTrials.gov posting and PubMed publication.
  • Multivariate analysis of reporting rates based on sponsor, phase, status, and modality.

Main Results:

  • Cell and gene therapy (CT) was identified as a significant factor associated with lower result reporting ratios on both ClinicalTrials.gov and in total disclosures.
  • Ex vivo gene therapy (GT) was associated with a higher result reporting ratio.
  • The overall reporting rate for CT trials was notably poor, necessitating further investigation.

Conclusions:

  • Cell and gene therapy (CT) trials exhibit a concerningly low rate of results disclosure, impacting overall clinical research transparency.
  • Ex vivo gene therapy (GT) demonstrates a positive association with improved result reporting.
  • Addressing the underreporting in CT trials is crucial for ethical research practices and requires exploring underlying causes and potential solutions.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K